Re-induction therapy in patients with acute myeloid leukemia not in complete remission after the first course of treatment.

Autor: Fu, Weijia, Hu, Yue, Lu, Guihua, Xu, Lili, Gao, Lei, Chen, Jie, Chen, Li, Tang, Gusheng, Ni, Xiong, Yang, Jianmin
Předmět:
Zdroj: Annals of Hematology; Feb2023, Vol. 102 Issue 2, p329-335, 7p
Abstrakt: A standard salvage regimen for patients with acute myeloid leukemia (AML) who are not in complete remission (CR) after initial induction therapy does not exist. We retrospectively investigated re-induction therapy for 151 patients with AML who did not achieve CR after the initial course between January 2014 and March 2021. The re-induction regimen did not correlate with the CR rate after the second course, whereas patients had similar 5-year overall survival (OS) and event-free survival (EFS) based on different re-induction regimens. Multivariable analysis revealed that International European Leukaemia Net (ELN) risk stratification independently predicted both OS and EFS among patients not in CR after the first course, although the re-induction regimen did not predict prognosis. Urgent salvage alloHSCT may improve the prognosis of patients with refractory AML. In summary, our study showed that the re-induction regimen did not significantly predict the prognosis of patients with AML not in CR after the first course of treatment. The development and selection of an efficient treatment algorithm for the treatment of AML remains a pressing research challenge. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz: